tiprankstipranks
Advertisement
Advertisement

CRVO Stock Latest News

CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
Company AnnouncementsCervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
2d ago
8K
CRVO
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
PremiumCompany Announcements
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
17d ago
8K
CRVO
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
PremiumCompany Announcements
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
21d ago
8K
CRVO
CervoMed’s neflamapimod shows efficacy in dementia with DLB
PremiumThe Fly
CervoMed’s neflamapimod shows efficacy in dementia with DLB
22d ago
CRVO
CervoMed price target lowered to $11 from $19 at Roth Capital
PremiumThe Fly
CervoMed price target lowered to $11 from $19 at Roth Capital
23d ago
CRVO
CervoMed price target raised to $21 from $15 at Chardan
PremiumThe FlyCervoMed price target raised to $21 from $15 at Chardan
23d ago
CRVO
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
Premium
Company Announcements
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
23d ago
8K
CRVO
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
Premium
Ratings
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
24d ago
CRVO
CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024
PremiumThe Fly
CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024
24d ago
CRVO
CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
PremiumRatings
CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target
24d ago
CRVO
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
PremiumCompany Announcements
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs
26d ago
CRVO
CervoMed announces presentations at AP/PD 2026 scientific conference
PremiumThe Fly
CervoMed announces presentations at AP/PD 2026 scientific conference
29d ago
CRVO
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
PremiumMarket NewsBuy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
1M ago
CRVO
TCRX
CervoMed Advances Neflamapimod With Phase 1 Completion
Premium
Company Announcements
CervoMed Advances Neflamapimod With Phase 1 Completion
1M ago
8K
CRVO
CervoMed completes Phase 1 volunteer study for neflamapimod
Premium
The Fly
CervoMed completes Phase 1 volunteer study for neflamapimod
1M ago
CRVO
CervoMed’s Neflamapimod Added to U.K. ALS Platform
PremiumCompany Announcements
CervoMed’s Neflamapimod Added to U.K. ALS Platform
2M ago
8K
CRVO
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target
PremiumRatings
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target
2M ago
CRVO
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
PremiumThe Fly
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
2M ago
CRVO
CervoMed Releases Updated Investor Presentation and Business Overview
PremiumCompany Announcements
CervoMed Releases Updated Investor Presentation and Business Overview
3M ago
8K
CRVO
CervoMed initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyCervoMed initiated with an Overweight at Cantor Fitzgerald
4M ago
CRVO
CervoMed Initiated With Buy Rating on Differentiated DLB Asset Neflamapimod and De-Risked Path to 2029 Launch
Premium
Ratings
CervoMed Initiated With Buy Rating on Differentiated DLB Asset Neflamapimod and De-Risked Path to 2029 Launch
4M ago
CRVO
CervoMed’s Promising Phase 2b Trial Results for DLB
Premium
Company Announcements
CervoMed’s Promising Phase 2b Trial Results for DLB
4M ago
8K
CRVO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >